EU pharma reform compromise: Tighter launch rules and antibiotic incentive voucher

EU PERSPECTIVES - A medicine approved in Brussels can take years to reach patients in Warsaw or Bucharest. A long-awaited compromise on the EU's pharmaceutical reform aims to narrow the gap between regulatory approval and patient access across the bloc, with new rules on medicine launch obligations and a revised incentive for developing antibiotics. The agreement now heads to the European Parliament's health committee on 18 March. Read more

Photo: Unsplash A final compromise text endorsed by EU ambassadors introduces a three-year deadline for medicines requested by Member States and adds new limits to the EU's exclusivity voucher designed to stimulate antibiotic development.